دورية أكاديمية
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
العنوان: | Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. |
---|---|
المؤلفون: | Mei, Matthew, Palmer, Joycelynne, Ni-Chun Tsai, Nicole, Simpson, Jennifer, O'Hearn, James, Stein, Anthony, Forman, Stephen, Spielberger, Ricardo, Cai, Ji-Lian, Htut, Myo, Nakamura, Ryotaro, Malki, Monzr M. Al, Herrera, Alex, Wong, Jeffrey, Nademanee, Auayporn |
المصدر: | Clinical Lymphoma, Myeloma & Leukemia; Sep2023, Vol. 23 Issue 9, pe268-e276, 9p |
قاعدة البيانات: | Complementary Index |
كن أول من يترك تعليقا!